Mary C Boulanger, Stephen B Lo, Joely A Centracchio, Brianna Jewett, Madison Freese, Mia Holtze, Jamie M Jacobs, Laura A Petrillo, Jessica Bauman, Areej El-Jawahri, Jennifer S Temel, Joseph A Greer
{"title":"Pilot Feasibility Trial of a Supportive Care Digital Application for Patients with Advanced Nonsmall Cell Lung Cancer.","authors":"Mary C Boulanger, Stephen B Lo, Joely A Centracchio, Brianna Jewett, Madison Freese, Mia Holtze, Jamie M Jacobs, Laura A Petrillo, Jessica Bauman, Areej El-Jawahri, Jennifer S Temel, Joseph A Greer","doi":"10.1089/jpm.2025.0066","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> Patients with advanced nonsmall cell lung cancer (NSCLC) experience burdensome symptoms, psychological distress, and poor quality of life (QOL). <b><i>Objective:</i></b> We developed and pilot-tested a digital health application (\"THRIVE\"), consisting of six modules designed to improve patients' symptom management and coping with NSCLC. <b><i>Design:</i></b> Randomized pilot feasibility trial. <b><i>Setting/Subjects:</i></b> Eligible patients included adults within 12 weeks of an advanced NSCLC diagnosis receiving care at a participating institution in the United States. <b><i>Measurements:</i></b> Participants completed baseline and 12-week assessments of QOL (Functional Assessment of Cancer Therapy-Lung), physical symptoms (MD Anderson Symptom Inventory; MDASI), psychological distress (Hospital Anxiety and Depression Scale), and coping (Brief COPE). The primary outcome was study feasibility, defined as ≥65% of approached patients consenting to participate; ≥70% of intervention participants completing ≥4 of 6 app modules; and ≥70% of the sample completing the 12-week assessments. We used the System Usability Scale (SUS) to assess intervention acceptability. <b><i>Results:</i></b> Of 232 patients approached, 135 (58.2%) provided consent, and 120 (51.7%) were randomized (Age<sub>mean</sub> = 67.90 years, 61.7% female, 90.8% White). Among intervention participants, 70.5% (43/61) completed ≥4 modules, with 77.3% reporting above-average SUS usability ratings for THRIVE. Ninety-four (78.3%) participants completed the 12-week assessments. <b><i>Conclusions:</i></b> Although the enrollment rate was lower than anticipated, patients with advanced NSCLC who received THRIVE met the feasibility criterion for app completion and reported high acceptability. These results support conducting a follow-up efficacy trial of THRIVE for improving patients' QOL, physical symptoms, and other psychosocial outcomes.</p>","PeriodicalId":16656,"journal":{"name":"Journal of palliative medicine","volume":" ","pages":"1210-1219"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of palliative medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/jpm.2025.0066","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Patients with advanced nonsmall cell lung cancer (NSCLC) experience burdensome symptoms, psychological distress, and poor quality of life (QOL). Objective: We developed and pilot-tested a digital health application ("THRIVE"), consisting of six modules designed to improve patients' symptom management and coping with NSCLC. Design: Randomized pilot feasibility trial. Setting/Subjects: Eligible patients included adults within 12 weeks of an advanced NSCLC diagnosis receiving care at a participating institution in the United States. Measurements: Participants completed baseline and 12-week assessments of QOL (Functional Assessment of Cancer Therapy-Lung), physical symptoms (MD Anderson Symptom Inventory; MDASI), psychological distress (Hospital Anxiety and Depression Scale), and coping (Brief COPE). The primary outcome was study feasibility, defined as ≥65% of approached patients consenting to participate; ≥70% of intervention participants completing ≥4 of 6 app modules; and ≥70% of the sample completing the 12-week assessments. We used the System Usability Scale (SUS) to assess intervention acceptability. Results: Of 232 patients approached, 135 (58.2%) provided consent, and 120 (51.7%) were randomized (Agemean = 67.90 years, 61.7% female, 90.8% White). Among intervention participants, 70.5% (43/61) completed ≥4 modules, with 77.3% reporting above-average SUS usability ratings for THRIVE. Ninety-four (78.3%) participants completed the 12-week assessments. Conclusions: Although the enrollment rate was lower than anticipated, patients with advanced NSCLC who received THRIVE met the feasibility criterion for app completion and reported high acceptability. These results support conducting a follow-up efficacy trial of THRIVE for improving patients' QOL, physical symptoms, and other psychosocial outcomes.
期刊介绍:
Journal of Palliative Medicine is the premier peer-reviewed journal covering medical, psychosocial, policy, and legal issues in end-of-life care and relief of suffering for patients with intractable pain. The Journal presents essential information for professionals in hospice/palliative medicine, focusing on improving quality of life for patients and their families, and the latest developments in drug and non-drug treatments.
The companion biweekly eNewsletter, Briefings in Palliative Medicine, delivers the latest breaking news and information to keep clinicians and health care providers continuously updated.